JP2024516363A5 - - Google Patents

Info

Publication number
JP2024516363A5
JP2024516363A5 JP2023562511A JP2023562511A JP2024516363A5 JP 2024516363 A5 JP2024516363 A5 JP 2024516363A5 JP 2023562511 A JP2023562511 A JP 2023562511A JP 2023562511 A JP2023562511 A JP 2023562511A JP 2024516363 A5 JP2024516363 A5 JP 2024516363A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
ribociclib
cancer
amsenestrant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516363A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/059700 external-priority patent/WO2022218956A1/en
Publication of JP2024516363A publication Critical patent/JP2024516363A/ja
Publication of JP2024516363A5 publication Critical patent/JP2024516363A5/ja
Pending legal-status Critical Current

Links

JP2023562511A 2021-04-12 2022-04-12 リボシクリブ及びアムセネストラントを含む組み合わせ Pending JP2024516363A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21315064 2021-04-12
EP21315064.2 2021-04-12
PCT/EP2022/059700 WO2022218956A1 (en) 2021-04-12 2022-04-12 Combination comprising ribociclib and amcenestrant

Publications (2)

Publication Number Publication Date
JP2024516363A JP2024516363A (ja) 2024-04-15
JP2024516363A5 true JP2024516363A5 (cg-RX-API-DMAC7.html) 2025-04-16

Family

ID=75825774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562511A Pending JP2024516363A (ja) 2021-04-12 2022-04-12 リボシクリブ及びアムセネストラントを含む組み合わせ

Country Status (7)

Country Link
US (1) US20240197739A1 (cg-RX-API-DMAC7.html)
EP (1) EP4322941A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516363A (cg-RX-API-DMAC7.html)
CN (1) CN117136053A (cg-RX-API-DMAC7.html)
AR (1) AR125331A1 (cg-RX-API-DMAC7.html)
TW (1) TW202304425A (cg-RX-API-DMAC7.html)
WO (1) WO2022218956A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3847157T3 (da) 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
WO2025085738A1 (en) 2023-10-18 2025-04-24 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4772247A2 (en) * 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
SG11201806829TA (en) * 2016-02-15 2018-09-27 Sanofi Sa 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
MX2022010425A (es) * 2020-03-06 2022-09-07 Olema Pharmaceuticals Inc Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.

Similar Documents

Publication Publication Date Title
JP2024516795A5 (cg-RX-API-DMAC7.html)
JP2023550149A5 (cg-RX-API-DMAC7.html)
JP2023516951A5 (cg-RX-API-DMAC7.html)
JP2023503309A5 (cg-RX-API-DMAC7.html)
RU2020107416A (ru) Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака
FI3849534T3 (fi) Yhdistelmähoidot
CA2501651A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
JP2016518387A5 (cg-RX-API-DMAC7.html)
JP2020521797A5 (cg-RX-API-DMAC7.html)
JP2013518124A5 (cg-RX-API-DMAC7.html)
JP2006500346A5 (cg-RX-API-DMAC7.html)
JP2016502981A5 (cg-RX-API-DMAC7.html)
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres
RU2019130325A (ru) ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ
JP2016094450A (ja) 薬物誘発性手足症候群を治療するための組成物および方法
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
Mornex et al. Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art
JP2021522246A5 (cg-RX-API-DMAC7.html)
JP2023531930A5 (cg-RX-API-DMAC7.html)
JP2025511402A5 (cg-RX-API-DMAC7.html)
JP2025511401A5 (cg-RX-API-DMAC7.html)
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
JP2011500650A5 (cg-RX-API-DMAC7.html)
FI3941466T3 (fi) Vafidemstat epävakaan persoonallisuushäiriön ei-aggressiivisen oireiden hoitoon
JP2019525924A5 (cg-RX-API-DMAC7.html)